MedTrace Logo

Single Ascending Dose Study of WAL0921 in Healthy Subjects

NCT05891366 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-04-10

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of WAL0921 in healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

WAL0921

Investigational product WAL0921

DRUG

Placebo

Placebo product

Sponsors & Collaborators

  • Walden Biosciences

    lead INDUSTRY

Principal Investigators

  • Andrew Blair, MD · Walden Biosciences, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-31
Primary Completion
2024-01-09
Completion
2024-01-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05891366 on ClinicalTrials.gov